Skip to main content

Biotech startups from the Basel Area confirm leading position

| News

Biotech startups from the Basel Area confirm leading position

10.09.2021

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also include several startups based in the Basel Area, mainly from the biotech sector. The Medtech firm Resistell even made it into the top ten, seven others are among the Top 100.

The 11th edition of the TOP 100 Swiss Startup Award was celebrated in Schlieren (img: evenito)

Venturelab has once again been busy handing out the TOP 100 Swiss Startup Awards. The rankings contain several startups from the Basel Area, with the Medtech company Resistell even making the lofty heights of the top ten firms. Based in Muttenz in the canton of Basel-Landschaft, Resistell has developed a particularly rapid test against antibiotic resistance and secured ninth place in the rankings.

The second-highest ranking from the Basel Area went to Tolremo Therapeutics AG (17th place). Likewise headquartered in Muttenz, this biotech firm is developing cancer therapies for precision medicine applications. It was also supported by BaseLaunch, the startup accelerator and incubator of the investment and innovation promotion agency Basel Area Business & Innovation.

Perseo Pharma AG, again based in Muttenz, registered a major improvement on the previous year, jumping from 60th place to 31st place. This makes it the third-highest ranked company from the Basel Area in the rankings. It develops therapeutic enzymes for the treatment of cancers and rare genetic diseases.

In addition, other Basel Area firms to make the rankings include Versameb (54th place), Alentis Therapeutics (57th place), Synendos Therapeutics (72th place) and Scailyte (98th place). Both Versameb and Alentis Therapeutics are headquartered at the Technologiepark Basel and received support from BaseLaunch. The former develops therapies on the basis of mRNA sequencing, while the latter develops molecules to treat advanced hepatic and renal fibrosis. Synendos Therapeutics, based at the Switzerland Innovation Park Basel Area in Allschwil in the canton of Basel-Landschaft, also received support from BaseLaunch and is working on an approach that aims to treat anxiety, mood and stress-related disorders. For its part, Scailyte is developing a software solution to detect diseases. The company was supported by Basel Area Business & Innovation during the process of establishing its headquarters at the Novartis Campus of the Switzerland Innovation Park Basel Area.

Due to the fact that only companies founded no longer than five years ago are considered for the TOP 100 Swiss Startup Awards, Venturelab has also produced a scale-up list. This table serves to honor startups founded between five and ten years ago, with companies from the Basel Area represented here too. These include the biotechnology firms Crispr Therapeutics AGPolyneuron Pharmaceuticals AG and T3 Pharmaceuticals AG. The latter two companies were also supported by BaseLaunch. In addition, Synendos Therapeutics AG was also named as the winner of a public vote award.

The eleventh edition of the TOP 100 Swiss Startup Award was organized by Venturelab and supported by Credit Suisse and the Swiss Venture Club. On this occasion, the award ceremony took place in the new startup space in Schlieren. The best startups are afforded an opportunity to present their businesses to a group of international investors. Among other aspects, these startups will benefit from reporting in several languages – including Chinese and Japanese.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

An intense and ambitious year for the Jura site of the Switzerland Innovation Park Basel Area

Despite the coronavirus pandemic, which has delayed some projects, the Jura site of the Switzerland Innovation Park Basel Area has...
Read More

VectivBio secures investments totaling 110 million dollars

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...
Read More

Polyphor receives up to 18 million dollars for development of antibiotics

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...
Read More

DayOne Accelerator applications open

We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!
Read More

Matériaux Sabag printing concrete elements

The Jura-based company Matériaux Sabag is now using a 3D printing solution to produce its concrete elements. This approach allows...
Read More

Monte Rosa Therapeutics banks 96 million US dollars

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...
Read More
1 30 31 32 33 34 41

Do you have a question? We'd like to hear from you.